Emerging infectious diseases: A proactive approach
暂无分享,去创建一个
[1] K. V. Raghavan,et al. New Vaccines against Epidemic Infectious Diseases. , 2017, The New England journal of medicine.
[2] J. Sachs,et al. The economic and social burden of malaria , 2002, Nature.
[3] J. Sachs,et al. The economic burden of malaria. , 2001, The American journal of tropical medicine and hygiene.
[4] Donald S. Shepard,et al. Economic Impact of Dengue Illness in the Americas , 2011, The American journal of tropical medicine and hygiene.
[5] David W. Stahle,et al. Megadrought and Megadeath in 16th Century Mexico , 2002, Emerging infectious diseases.
[6] J. Farrar,et al. Establishing a Global Vaccine-Development Fund. , 2015, The New England journal of medicine.
[7] D. Jamison,et al. The Inclusive Cost of Pandemic Influenza Risk , 2016 .
[8] C W Potter,et al. A history of influenza , 2001, Journal of applied microbiology.
[9] A. Fauci,et al. The challenge of emerging and re-emerging infectious diseases , 2004, Nature.
[10] Richard D. Smith,et al. The economic impact of SARS: How does the reality match the predictions? , 2008, Health Policy.
[11] V. Dzau,et al. Assessment of economic vulnerability to infectious disease crises , 2016, The Lancet.
[12] Nico Pfeifer,et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.
[13] M. Thomas,et al. The economic impact of Ebola on sub-Saharan Africa : updated estimates for 2015 , 2015 .
[14] M. Kuehn,et al. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions , 2015, Nature Reviews Microbiology.
[15] Bruce Y. Lee,et al. The cost of an Ebola case , 2015, Pathogens and global health.
[16] Andrew Burns,et al. Evaluating the economic consequences of avian influenza , 2006 .
[17] A. Hill,et al. Viral vectors as vaccine platforms: from immunogenicity to impact. , 2016, Current opinion in immunology.
[18] Anthony S Fauci,et al. The perpetual challenge of infectious diseases. , 2012, The New England journal of medicine.